While attending the 2025 World Conference on Genitourinary Cancers (World GU), Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke with various experts and presenters about critical developments that may improve the treatment of patients with different genitourinary malignancies. Bupathi is executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers. Garmezy is associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at SCRI and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers.
In this episode, Bupathi and Garmezy explored the conference halls to chat with several colleagues and peers who presented on topics related to the care of those with prostate cancer, kidney cancer, bladder cancer, and other genitourinary malignancies. The hosts exchanged ideas on how to elevate the quality of care for these patients in a community-based setting with the following attendees:
· Mehmet Asim Bilen, MD, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University;
· Sid Sadler, a patient advocate and survivor of kidney cancer;
· Kerry R. Schaffer, MD, an assistant professor of Medicine in the Division of Hematology and Oncology of the Department of Medicine at Vanderbilt University Medical Center;
· Mark T. Fleming, MD, a board-certified medical oncologist at Virginia Oncology Associates;
· Jeff Yorio, MD, a medical oncologist who serves as the Central Texas Research Site Leader for Texas Oncology and SCRI;
· Mike Lattanzi, MD, a medical oncologist with a focus on genitourinary malignancies at Texas Oncology;
· Elizabeth Kessler, MD, an associate professor of Medical Oncology at the University of Colorado;
· Benjamin L. Maughan, MD, PharmD, an associate professor in the Division of Medical Oncology at Huntsman Cancer Institute;
· and Alan Tan, MD, a genitourinary oncology and melanoma specialist at Vanderbilt-Ingram Cancer Center as well as an assistant professor of Medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center.